Leads to Development opens new offices in London and Lyon
22 Oct 2010
Leads To Development (L2D), a specialist in non-clinical
development of novel therapeutics, is opening new offices in London, UK
and Lyon, France to cater for increasing demand for its services.
This comes just one year after the establishment of the Paris-based
L2D is a pioneering business created to manage the non-clinical
aspects of development projects, allowing biotech and pharmaceutical
companies to bring in expertise as and when needed without having to
build additional headcount and infrastructure.
Dr Jonathan Kearsey, founder and director of L2D explained:
“We’ve seen substantial demand and uptake of our services across
Europe. The UK and France are important markets for us and opening
satellite offices in London and Lyon is an important step in L2D’s
"The London office is based at the London Bioscience Innovation
Centre and will allow biotech companies in the London, Oxford and
Cambridge triangle to have faster and easier access to our
expertise. Lyon has also shown itself to be an area of growth with
great future potential and having an office at the centre of the
Lyonbiopôle (Rhone –Alps) cluster will further enhance our client
All non-clinical development activities can be outsourced to L2D
which will manage part, or all, of the therapeutic programme from
development plan design and writing through to the submission of the
clinical trial application.
Non-clinical development encompasses all development activities
required to be able to submit a clinical trial application, whatever
the phase, including preclinical, as well as all the non-clinical
aspects of phase I, II and III clinical trials.
To complement these activities, L2D also provides business and
strategic advice (including due diligence) to investors, biotechs,